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A B S T R A C T
Background
Croup is thought to be triggered by a viral infection and is characterised by respiratory distress due to upper airway inflammation
and swelling of the subglottic mucosa in children. Mostly it is mild and transient and resolves with supportive care. In moderate to
severe cases, treatment with corticosteroids and nebulised epinephrine (adrenaline) is required. Corticosteroids improve symptoms
but it takes time for a full effect to be achieved. In the interim, the child is at risk of further deterioration. This may rarely result in
respiratory failure necessitating emergency intubation and ventilation. Nebulised epinephrine may result in dose-related adverse effects
including tachycardia, arrhythmias and hypertension and its benefit may be short-lived. Helium-oxygen (heliox) inhalation has shown
therapeutic benefit in initial treatment of acute respiratory syncytial virus (RSV) bronchiolitis and may prevent morbidity and mortality
in ventilated neonates. Heliox has been used during emergency transport of children with severe croup and anecdotal evidence suggests
that heliox relieves respiratory distress.
Objectives
To examine the effect of heliox on relieving symptoms and signs of croup, as determined by a croup score (a tool for measuring the
severity of croup).
To examine the effect of croup on rates of admission or intubation (or both), through comparisons of heliox with placebo or any active
intervention(s) in children with croup.
Search methods
We searched CENTRAL 2013, Issue 10, MEDLINE (1950 to October week 5, 2013), EMBASE (1974 toNovember 2013), CINAHL
(1982 to November 2013), Web of Science (1955 to November 2013) and LILACS (1982 to November 2013). In addition, we
searched two clinical trials registries: the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP)
and clinicaltrials.gov (searched 12 November 2013).
Selection criteria
Randomised controlled trials (RCTs) and quasi-RCTs comparing the effect of helium-oxygen mixtures with placebo or any active
intervention(s) in children with croup.
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Data collection and analysis
Two review authors independently identified and assessed citations for inclusion. A third review author resolved disagreements. We
assessed included trials for allocation concealment, blinding of intervention, completeness of outcome data, selective outcome reporting
and other potential sources of bias. We reported mean differences for continuous data and odds ratios for dichotomous data. We
descriptively reported data not suitable for statistical analysis.
Main results
We included three RCTs with a total of 91 participants. One study compared heliox 70%/30% with 30% humidified oxygen admin-
istered for 20 minutes in children with mild croup and found no statistically significant differences in the overall change in croup
scores between heliox and the comparator. In another study, children with moderate to severe croup were administered intramuscular
dexamethasone 0.6 mg/kg and either heliox 70%/30% with one to two doses of nebulised saline, or 100% oxygen with one to two
doses of nebulised racaemic epinephrine for three hours. In this study, the heliox group’s croup scores improved significantly more at all
time points from 90 minutes onwards. However, overall there were no significant differences in croup scores between the groups after
four hours using repeated measures analysis. In a third study, children with moderate croup all received one dose of oral dexamethasone
0.3 mg/kg with heliox 70%/30% for 60 minutes in the intervention group and no treatment in the comparator. There was a statistically
significant difference in croup scores at 60 minutes in favour of heliox but no significant difference after 120 minutes. It was not possible
to pool outcomes because the included studies compared different interventions and reported different outcomes. No adverse events
were reported.
Authors’ conclusions
There is some evidence to suggest a short-term benefit of heliox inhalation in children with moderate to severe croup who have been
administered oral or intramuscular dexamethasone. In one study, the benefit appeared to be similar to a combination of 100% oxygen
with nebulised epinephrine. In another study there was a slight change in croup scores between heliox and controls, with unclear
clinical significance. In another study in mild croup, the benefit of humidified heliox was equivalent to that of 30% humidified oxygen,
suggesting that heliox is not indicated in this group of patients provided that 30% oxygen is available. Adequately powered RCTs
comparing heliox with standard treatments are needed to further assess the role of heliox in children with moderate to severe croup.
P L A I N L A N G U A G E S U M M A R Y
Helium-oxygen (heliox) treatment for croup in children
Croup is an acute illness commonly seen in children up to six years of age but mostly by the age of two. It is triggered by viral
infections causing upper airway obstruction with varying degrees of respiratory distress. Mostly, it is mild and transient and resolves
with supportive care. Croup is characterised by a barking cough, hoarseness, varying degrees of inspiratory stridor (abnormal breathing
sound) and chest wall retractions and is usually preceded by one to three days of upper respiratory tract infection symptoms. The peak
croup seasons are autumn and winter but can occur at any time.
Corticosteroids are an accepted treatment for moderate to severe croup, supplemented inmore severe cases by nebulised epinephrine and
oxygen. Epinephrine is often effective and safe but can have undesired effects (such as increased heart rate and anxiety). Corticosteroids
improve croup symptoms but it takes time for their full effect to be achieved. In the meantime the child remains at risk of deterioration.
This may rarely result in the development of respiratory failure, which may require emergency intubation and ventilation. Therefore,
finding a safe and effective treatment to bridge the gap between the administration and effectiveness of the corticosteroids is important
for clinical practice.
Some studies have shown a benefit of using heliox in children with croup. Heliox, a gas with lower density than air or oxygen, is believed
to reduce the resistance to gas flow in narrowed upper airways, potentially improving symptoms and signs of respiratory distress. This
review found three randomised controlled trials (RCTs) assessing the effect of heliox in 91 children with croup. Heliox did not appear
to be more effective than administration of 30% oxygen in children with mild croup. In children with moderate to severe croup who
had been administered oral or intramuscular corticosteroids, heliox appeared to be at least as effective as continuous 100% oxygen
with one to two doses of nebulised racaemic epinephrine (adrenaline as a fine spray) in one study. It was slightly more effective than no
treatment in another study. There were no adverse effects or outcomes reported. The included trials were small and had a number of
methodological limitations. Further methodologically well-designed RCTs with more participants are needed to further assess the role
of heliox in managing children with moderate to severe croup. The evidence is current to November 2013.
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B A C K G R O U N D
Description of the condition
Croup (also know as viral laryngotracheobronchitis), is a common
respiratory syndrome in children, which may progress to an acute
respiratory obstruction. It is characterised by a barking cough,
hoarseness, varying degrees of inspiratory stridor and chest wall
retractions. It is usually preceded by a one to three-day period
of viral upper respiratory tract infection symptoms. Croup com-
monly affects children up to the age of six years, with the highest
incidence in the second year of life (Denny 1983; Rittichier 2000).
A seasonal variation in the occurrence of croup, with a peak in
the autumn and winter, has been reported (Denny 1983; Segal
2005). Two commonly used methods for assessing the severity of
croup are the Westley and Taussig Croup Scales (Taussig 1975;
Westley 1978). The croup score is assigned based on the following
observed parameters: level of consciousness, stridor, colour, air en-
try and retractions. The Westley croup score has numerical values
ranging from zero to 17. Values less than four correspond to mild
croup, four to six to moderate croup and more than six to severe
croup. The Taussig scale also has numerical values ranging from
zero to 15. A score of less than four corresponds to mild croup,
four to seven corresponds to moderate croup and more than seven
corresponds to severe croup (Taussig 1975; Westley 1978).
Croup is thought to be triggered by a viral infection, most com-
monly by human parainfluenza virus (HPIV), particularly HPIV
type 1 and less commonly by influenza virus, respiratory syncy-
tial virus (RSV), rhinovirus, adenovirus, enteroviruses and My-
coplasma pneumoniae (M. pneumoniae) (Denny 1983; Marx 1997;
Segal 2005). Viral invasion of the subglottic mucosa causes in-
flammation and oedema, leading to narrowing of the upper air-
way. As this narrowing progresses, the pressure gradient necessary
to move air through the upper airway becomes greater, leading
to an increased effort in breathing. This may result in fatigue of
the respiratory muscles and subsequently lead to respiratory fail-
ure, requiring emergency intubation. Systemic, oral or nebulised
corticosteroids are the currently accepted treatment for moderate
to severe croup, supplemented in more severe cases by nebulised
epinephrine (Bjornson 2011) and oxygen. Antibiotics do not play
a role in the treatment of acute croup. Corticosteroids have been
shown to improve symptoms of croup but it takes time for their
full effect to be achieved (Russell 2012). Nebulised budesonide
has been shown to have a beneficial effect as early as two hours
after administration (Fitzgerald 1996; Klassen 1998) but in the
meantime the child remains at risk of deterioration and of de-
veloping respiratory failure, requiring emergency intubation and
ventilation.
Description of the intervention
Helium is a biologically inert, colourless, odourless and non-com-
bustible gas and was first discovered in 1868 by Jannsen and Lock-
yer. In the early 1930s Barach pioneered the successful use of a
helium-oxygen mixture (heliox) in the treatment of adults and
children with asthma and upper airway obstruction (Barach 1935;
Barach 1936). However, it was not until the 1980s that helium-
oxygen mixtures regained popularity, possibly due to the rising
mortality from asthma (Robin 1988). This led to an increase in
clinical trials assessing the effect of heliox in the management of
acute upper and lower airway obstructive disorders in children
(Cambonie 2006; Grozs 2001; Hollman 1998; Martinon-Torres
2002). Heliox is used in concentrations of helium/oxygen of 80%/
20%, 60%/40% or 70%/30%.
How the intervention might work
Heliox has a similar viscosity and a substantial sevenfold lower
density than air and when combined with oxygen results in heliox,
a gas mixture with an up to threefold (heliox 80/20) lower density
than air (Papamoschou 1995). The density of a gas mixture is pro-
portional to the Reynolds number (Re), a dimensionless ratio of
the inertial to the viscous force and will thus have an effect on the
type of gas flow present in the airway. It is known that turbulent
flow occurs when Re > 3000 and laminar flow occurs when Re
< 2000 (Glauser 1969). Pathological narrowing of the airway, as
seen in croup, will lead to increased turbulence and higher gas flow
resistance, resulting in an increased breathing effort. In theory, a
gas of low density, such as heliox, should create a less turbulent
or even laminar flow, by reducing the Reynolds number, leading
to a decrease in resistance to gas flow and the work of breathing
(Houck 1990). Heliox is also believed to improve gas exchange,
due to a delivery of increased tidal volume as a result of lowering
the resistive forces within the airway (Katz 2001; Katz 2003). A
Cochrane Review investigating the role of heliox inhalation ther-
apy in infants with RSV bronchiolitis concludes that the addition
of heliox therapy to standard medical care may significantly re-
duce a clinical score evaluating respiratory distress in the first hour
after starting treatment (Liet 2010). Similarly, a Cochrane Review
in children with asthma suggests that heliox might have benefi-
cial effects in patients (children or adults) with severe obstruction
(Rodrigo 2010).
Why it is important to do this review
Croup can cause anxiety and distress to affected children and
their parents. In mild cases, supportive treatment may suffice but
in moderate to severe cases, more aggressive therapy may be re-
quired to prevent exhaustion and respiratory failure. The avail-
able treatment options for croup are limited. Corticosteroids take
time for their clinical effects to be achieved.Nebulised epinephrine
(adrenaline) is widely used. It has a rapid onset and short-lived
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benefit but can be associated with dose-related side effects such
as tachycardia, hypertension and arrhythmias. Treatment of croup
with heliox has demonstrated a beneficial effect, albeit in a small
numbers of patients (Beckmann 2000; DiCecco 2004; Duncan
1979; Nelson 1982; Smith 1999) and in one study the benefit ap-
peared to be no different to nebulised epinephrine (Weber 2001).
No significant evidence of benefit was reported in the previous
version of this review (Vorwerk 2010), but there are new data from
a Spanish randomised controlled trial (RCT) to suggest that he-
liox, when added to corticosteroids, clinically improves moderate
croup (Pardillo 2009). Also a recently published retrospective co-
hort study indicates that heliox, when added to standard treatment
for transporting critically ill children with croup, provides rapid
and sustained improvement in croup scores with no extension of
length of stay in the intensive care unit (ICU) (Kline-Krammes
2012). There is a need for an updated review of the evidence re-
garding the role of heliox in children with croup to guide clinical
practice.
O B J E C T I V E S
To examine the effect of heliox on relieving symptoms and signs
of croup, as determined by a croup score (a tool for measuring the
severity of croup).
To examine the effect of croup on rates of admission or intubation
(or both), through comparisons of heliox with placebo or any
active intervention(s) in children with croup.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) and quasi-RCTs comparing
the effect of helium-oxygen mixtures with placebo or any active
intervention(s).
Types of participants
Children with the clinical diagnosis of croup or laryngotracheo-
bronchitis. We excluded other upper airway obstruction condi-
tions such as epiglottitis, foreign body inhalation or peritonsillar
abscess.
Types of interventions
We included studies where the effect of heliox was compared to
placebo or any active intervention(s); and where similar routes of
administration were used for both groups.
Types of outcome measures
Primary outcomes
1. Change in croup score.
Secondary outcomes
1. Change in respiratory rate.
2. Change in oxygen requirements.
3. Change in heart rate.
4. Rate and duration of hospitalisation.
5. Rate and duration of intubation.
6. Rate and duration of admission to paediatric intensive care
units.
7. Rate of return to medical care for ongoing croup symptoms.
8. Parental anxiety.
9. Adverse events.
10. Other reported outcomes.
Search methods for identification of studies
Electronic searches
We conducted an updated search in the Cochrane Central Reg-
ister of Controlled Trials (CENTRAL) 2013, Issue 10, part of
The Cochrane Library, www.thecochranelibrary.com (accessed 12
November 2013), which contains the Acute Respiratory Infections
(ARI) Group’s Specialised Register, MEDLINE (January 2009 to
Octoberweek 5, 2013), EMBASE (May 2009 toNovember 2013),
Web of Science (1955 to November 2013) and LILACS (1982 to
November 2013). Details of the previous search are in Appendix
1.
MEDLINE and CENTRAL were searched using the following
terms. The search terms were adapted for EMBASE (Appendix
2), CINAHL (Appendix 3), Web of Science (Appendix 4) and
LILACS (Appendix 5).
MEDLINE (Ovid)
1 Croup/
2 croup.tw.
3 laryngotracheit*.tw.
4 laryngotracheo*.tw.
5 laryngo tracheo bronchit*.tw.
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6ParainfluenzaVirus 2,Human/ or parainfluenza virus 1, human/
or parainfluenza virus 3, human/
7 parainfluenza*.tw.
8 or/1-7
9 Helium/
10 helium*.tw,nm.
11 heliox.tw,nm.
12 (heo2 or he-o2 or he o2).tw,nm.
13 or/9-12
14 8 and 13
There were no language or publication restrictions.
Searching other resources
We searched two international clinical trials registries (last searched
12 November 2013): the World Health Organization Interna-
tional Clinical Trials registry Platform (WHO ICTRP) and clin-
icaltrials.gov for any ongoing or unpublished trials. We also
searched the references of review articles and all reports reviewed
in full text to find other potentially eligible studies. We contacted
the trial authors of the included studies and a leading medical gas
supplier, British Oxygen Company (BOC), to enquire whether
they knew of any further published or unpublished trials.
Data collection and analysis
Selection of studies
Two review authors (IM and NS) independently assessed the titles
and abstracts of all citations to identify potentially relevant reports.
All review authors agreed on a list of reports which were reviewed
in full, to determine whether they fulfilled the inclusion criteria.
Agreement about trial inclusion was reached by consensus.
Data extraction and management
The review authors independently extracted data on:
1. design (description of randomisation, use of blinding,
allocation concealment, handling of study withdrawals);
2. participants (total number, setting, age, exclusions);
3. intervention (type of helium-oxygen mixture, route of
intervention, control group intervention, study duration); and
4. outcomes (primary, secondary, outcome analysis).
Weused a standard data extraction formandwe reached agreement
by consensus.
Assessment of risk of bias in included studies
The review authors assessed the risk of bias in the included studies
by using The Cochrane Collaboration’s ’Risk of bias’ tool, address-
ing the following domains (Higgins 2011).
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel; blinding of
outcome assessment.
4. Incomplete outcome data.
5. Selective reporting.
6. Other sources of bias.
Unit of analysis issues
We analyzed the outcomes of individual patients. In studies where
the unit of analysis (individual patients) was not the same as the
unit of randomisation, such as is the case in cluster-randomised
trials or cross-over trials, we planned to use the methods described
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011) to adjust for the effect of clustering. In case of re-
peatedmeasures over time (such as measurement of croup scores at
different time points after receiving the intervention) we planned
to select a single time point andmeta-analyse only data at this time
for studies in which it was presented (Higgins 2011). We planned
to select a short-term time point as this is clinically relevant for
studies comparing heliox and other treatments for children with
croup.
Dealing with missing data
We contacted the authors of the included studies to obtain missing
data.
Assessment of heterogeneity
We assessed the included studies for clinical and methodological
heterogeneity. We planned to assess statistical heterogeneity by
calculating the P value of the Chi2 test and the I2 statistic with an
I2 statistic of 50% or more considered as significant heterogeneity.
Data synthesis
Wepresented continuous outcomes, such as change in croup score,
as mean difference (MD) with 95% confidence interval (CI). In
case pooled studies reported a different croup score at the same
time points, we planned to combine the outcomes by using the
standardised mean difference (SMD) with 95% confidence inter-
val (CI).We planned to use themethods described in theCochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011)
to calculate the SMD.
If standard deviations or confidence intervals (required for cal-
culating the SMD) were not available from the study reports we
used methods as described in the Cochrane Handbook for System-
atic Reviews of Interventions (Higgins 2011) to impute the missing
standard deviations from the standard error of the mean by multi-
plying by the square root of the sample size or from CIs from the
mean, whichever one was provided in the report.
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We presented dichotomous variables, such as proportion of hos-
pital admissions, as odds ratio (OR) with 95% CI. We reported
all identified adverse events.
We planned to pool data using both fixed-effect and random-
effectsmodels as described in theCochrane Handbook for Systematic
Reviews of Interventions and to explore the impact of each on the
overall treatment effect estimate (Higgins 2011).
Sensitivity analysis
Weplanned to investigate the impact of heterogeneity on the over-
all estimated effect of the intervention.
R E S U L T S
Description of studies
Results of the search
An updated search was conducted in November 2013 and iden-
tified 41 trial reports. Twenty-one titles were excluded after pre-
liminary screening; 20 were considered potentially eligible. After
abstract review, 17 studies did not meet the inclusion criteria and
were excluded. Three studies met the inclusion criteria (Figure 1).
The previous search conducted in June 2009 identified 45 trial
reports with two studies meeting the inclusion criteria.
Figure 1. Flow diagram of study selection
Included studies
We identified three studies (with a total of 91 participants) suit-
able for inclusion in this review. Two studies were published in
English and one in Spanish. All trials included in the review are
randomised controlled trials and the study participants have sim-
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ilar characteristics in terms of age and sex distribution. The char-
acteristics of included studies are described in the Characteristics
of included studies table and summarised in Table 1.
The trial by Terregino 1998 enrolled childrenwith mild croup aged
between six months and four years, presenting to the Emergency
Department. It was a small study with 15 participants; eight re-
ceived heliox and seven received 30% oxygen, both delivered via
humidification. Children were excluded from entering the study if
they had a presumed diagnosis of epiglottitis, a history of chronic
upper airway obstruction, if they were in severe respiratory distress
or their oxygen requirements exceeded 2 L/min to maintain an
oxygen saturation of at least 95%. The treatments were delivered
via a tight-fittingmask for a 20-minute period.No additional treat-
ments were given to the study participants. The main outcome
of the study was a change in Westley croup score (Westley 1978)
at 20 minutes. Other outcomes were measured at five-minute in-
tervals for 20 minutes and they included heart rate, respiratory
rate and oxygen saturation. The difference in the mean baseline
croup scores between the intervention and comparator groups was
not significant. No adverse events were reported during the study
period and all patients were discharged from the Emergency De-
partment.
In the study byWeber 2001, 29 children aged between six months
and three years with a diagnosis of moderate to severe croup, de-
fined as a modified Taussig 1975 croup score ≥ five or a score of
three in any of the five categories, were enrolled from the Emer-
gency Department. All children received continuous cool mist
and 0.6 mg/kg of intramuscular dexamethasone. Fourteen chil-
dren were then randomised to receive heliox and 15 children were
randomised to receive 100% oxygen plus one to two doses of neb-
ulised racaemic epinephrine. Gas therapy was administered via a
facemask or tent house continuously for three hours followed by
a further 60-minute observation period. The primary outcome
measure was the change in croup score over time (at 30, 60, 90,
120, 150, 180 and 240 minutes) and the secondary outcomes
were changes in oxygen saturation, respiratory rate and heart rate.
There was no significant difference in the mean baseline croup
score between the intervention and comparator group. No adverse
events were reported during the study.
Pardillo 2009 enrolled 47 children aged between 6 and 36 months
with moderate croup (defined as a Taussig score between five and
eight). A single dose of 0.3 mg/kg of dexamethasone was admin-
istered orally to all study participants. Heliox was administered to
24 children via a mask with a reservoir to prevent re-inhalation
for a period of one hour and 23 children received no treatment
unless their oxygen saturations fell to below 92% during the study,
in which case oxygen was administered by nasal prongs. Children
were excluded if they had congenital or acquired cardiac condi-
tions, bronchopulmonary dysplasia, stenosis or malformations of
the trachea, bronchospasm at diagnosis, intolerance of oral dex-
amethasone or if they had been treated with corticosteroids in the
previous two weeks. The main outcome measures were changes in
the Taussig croup score and respiratory rate, which were analyzed
at 60 and 120 minutes. The other outcome measures included
were: need for nebulised rescue epinephrine, admission rate and
re-consultation within the following 72 hours. There was no sig-
nificant difference in the mean baseline croup score or respira-
tory rate between the intervention and control group. No adverse
events were reported during the study.
Excluded studies
The previous search in 2009 excluded 43 reports of which 10 were
considered potentially relevant but excluded after a full-text review
(Characteristics of excluded studies table). Two were case series of
children with post-intubation or refractory viral croup (Duncan
1979; Nelson 1982). Smith 1999, Beckmann 2000 and DiCecco
2004 reported cases of helium-oxygen treatment in croup. Iglesias
2007 conducted a prospective, uncontrolled cohort study includ-
ing croup and other airway obstruction. The other excluded papers
were non-systematic reviews addressing different aspects of croup
management (Gupta 2005; Johnson 2009; Myers 2004; Myers
2006).
We conducted an updated search in March 2013 and excluded
38 reports. Three records were also excluded in the 2009 review
(Beckmann 2000; Duncan 1979; Myers 2006). Of the 17 new
records identified in the 2013 search seven were excluded after a
preliminary title review. Ten studies assessed after retrieving the
full text were subsequently excluded; five were not RCTs and five
were literature reviews (Brown 2002; Choi 2012; Frazier 2010;
Kaditis 1998; Kline-Krammes 2012; Nicolai 2012; Pitluk 2011;
Rosekrans 1998; Wald 2010; Wright 2005) (see Characteristics of
excluded studies).
Risk of bias in included studies
The methodological quality of all included studies as judged by
the review authors is illustrated in Figure 2 and in the Risk of bias
in included studies tables.
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Figure 2. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
Allocation
Allocation was adequately concealed in two of the three trials.
Terregino 1998 used sequentially numbered, sealed envelopes and
Weber 2001 used computer randomised allocation. Pardillo 2009
did not describe how concealment was carried out despite using a
computer program for randomisation.
Blinding
The trials by Terregino 1998 and Weber 2001 are considered to
have a low risk of bias as the participants and outcome assessors
were blinded; only the respiratory therapists were not blind to
treatment allocation. The trial by Pardillo 2009 is considered to
have a high risk of performance and detection bias because neither
the participants nor the assessors were blinded to treatment.
Incomplete outcome data
There was no evidence of missing outcome data in the Terregino
1998 study and no study participants were lost to follow-up. The
trial byWeber 2001 is categorised as high risk of bias because there
is insufficient explanation of why some participants were excluded
from the study and also no raw data for the main outcomes of the
study were provided. There was no evidence of missing outcome
data in the Pardillo 2009 study and therefore it is categorised as
having a low risk of attrition bias even though there is no explana-
tion as to why some excluded participants did not meet the study
inclusion criteria.
Selective reporting
Terregino 1998 reported all of the expected study outcomes (low
risk of reporting bias). The study by Weber 2001 did not present
expected study outcomes at any of the time points. Pardillo 2009
reported expected major outcome data but failed to report if any
participants required supplementary oxygen.
Other potential sources of bias
The study by Terregino 1998 used a convenience sample which
carries a potential risk of bias. There may also be further potential
risk of bias in the trial by Weber 2001 because of the lack of
outcome data. None of the studies disclosed any funding sources
and/or potential conflicts of interest.
Effects of interventions
Primary outcome
Change in croup score
The effect of heliox on symptoms and signs of croup, presented
as change in croup score between pre- and post-intervention was
reported in all three included studies. The croup scores were mea-
sured at different time points after the interventions: at 20minutes
in Terregino 1998, at 30, 60, 90, 120, 150, 180 and 240 minutes
in Weber 2001 and at 60 and 120 minutes in Pardillo 2009. In
the Terregino 1998 study the mean change in croup scores after
20 minutes of treatment favoured the intervention group (mean
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difference (MD) of change 0.83, 95% confidence interval (CI)
95% -0.7 to 2.36) (Analysis 1.1). The Weber 2001 study did not
present any raw croup scores (except in graphical form) at themea-
sured time points. In the Pardillo 2009 study the mean difference
(MD) in croup scores measured in both groups at 60 minutes was
statistically significant and in favour of the heliox group: MD -
1.12 (95% CI -2.06 to -0.18) (Analysis 2.2) and at 120 minutes
was not statistically significant with MD -0.71 (95% CI -1.72 to
0.30) (Analysis 2.3).
The Pardillo 2009 study compared changes in croup scores in
children with moderate croup (Taussig scale five to six) and those
with severe croup (Taussig scale seven to eight) and found a more
significant improvement in those with severe croup.
We only used data that were available from the publications, as no
additional data were obtained from the authors of the included
studies.
Secondary outcomes
Only data from Terregino 1998 and Pardillo 2009 were available
for analysis.
1. Change in respiratory rate
In the Terregino 1998 study the MD in change of respiratory rate
between pre- and post-intervention at 20 minutes was 6.4 (95%
CI -1.38 to 14.18) (Analysis 1.4). In the Pardillo 2009 study the
respiratory rate was more reduced in the heliox group than in the
control group both at 60 and at 120 minutes. The MD in change
of respiratory rate between pre- and post-intervention at 60 and
120 minutes was -4.94 (95% CI -9.66 to -0.22) (Analysis 2.4)
and -3.17 (95% CI -7.83 to 1.49) (Analysis 2.5), respectively.
There were no statistically significant differences between treat-
ment groups in respiratory rate (P = 0.94) in theWeber 2001 study
(no absolute numbers reported).
2. Change in oxygen requirements
The need for oxygen was not reported in any of the three included
trials. However, oxygen saturation of the included children was
reported in Terregino 1998 and Weber 2001. Terregino 1998 re-
ports that the mean oxygen saturation was stable over time in the
two groups. There were no statistically significant differences be-
tween treatment groups in arterial oxygen saturation (P = 0.28) in
the Weber 2001 study (no absolute numbers reported).
3. Change in heart rate
In the Terregino 1998 study, the MD in change of heart rate pre-
and post-intervention at 20 minutes was 14.5 (95% CI -8.49 to
37.49) (Analysis 1.3), favouring heliox. There were no statistically
significant differences between treatment groups in heart rate (P
= 0.29) in theWeber 2001 study (no absolute numbers reported).
In the Pardillo 2009 study, this outcome was not reported.
4. Rate and duration of hospital admission
In the Terregino 1998 study, all patients were discharged from the
emergency department. In the Pardillo 2009 study two patients in
the control group and one in the treatment groupwere hospitalised
(P = 0.609) and the odds ratio (OR) for the proportion of patients
who were admitted was 0.46 (95% CI 0.04 to 5.41) (Analysis
2.6). The OR favoured heliox. This outcome is not reported in
the Weber 2001 study.
5. Rate and duration of intubation
None of the study participants in the three included studies were
reported as requiring intubation.
6. Rate and duration of admission to paediatric intensive
care units
In the Pardillo 2009 study two patients in the heliox group (8.3%)
and two in the control group (8.7%) re-presented at the emergency
department within 72 hours of first presentation (P = 1) (Analysis
2.6). The Terregino 1998 and Weber 2001 studies do not report
this outcome.
7. Rate of return to medical care for ongoing croup
symptoms
The Terregino 1998 study did not report whether there were any
patients who re-presented to the hospital. In the Pardillo 2009
study the OR for the proportion of patients who re-presented to
hospital in the 72 hours following the intervention was 0.95 (95%
CI 0.12 to 7.41) (Analysis 2.7) and The OR favoured heliox.
8. Parental anxiety
This outcome was not reported in the three included studies.
9. Adverse events
There were no reported adverse events in any of the three included
trials. Terregino 1998 mentions there was “no recorded complica-
tion”.
10. Other reported outcomes
Terregino 1998 reports that none of the participating children
required administration of racaemic epinephrine.TheWeber 2001
study reports that “four patients in the epinephrine arm and three
in the Heliox arm received a second dose of racaemic epinephrine
and saline placebo, respectively. Outcomes for both groups were
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similar”. In the Pardillo 2009 study the OR for the proportion
of participants who required rescue adrenaline was 0.16 (95% CI
0.02 to 1.46) (Analysis 2.1). The other studies did not report data
contributing to this outcome. The OR favoured heliox.
D I S C U S S I O N
Summary of main results
Only three RCTs with a total of 91 participants (Terregino 1998;
Weber 2001; Pardillo 2009) assessed the effect of heliox inhalation
as treatment in children with a diagnosis of croup. Terregino 1998
comparedhelium-oxygen (70/30) inhalationwith humidified oxy-
gen (30%).Weber 2001 compared helium-oxygen (70/30) inhala-
tion with oxygen (100%) and nebulised racaemic epinephrine and
Pardillo 2009 compared heliox 70/30 with no treatment. Overall,
in all studies there wasmore improvement in the croup scores from
pre- to post-intervention with heliox than with the comparator in-
tervention, although it did not reach statistical significance in two
of the studies. There were no significant changes in heart rate, res-
piratory rates or oxygen saturation between the intervention and
comparison groups. There were no adverse events and there was
no need for intubation reported in any of the study participants.
Some patients were admitted to hospital and some re-presented at
the Emergency Department in the Pardillo 2009 study. The study
by Weber 2001 lacked data on the main outcomes and we were
unable to obtain data after contacting the authors. Therefore, it is
difficult to interpret the findings of this study.
Overall completeness and applicability of
evidence
In the case series described by Duncan 1979, seven children (aged
from newborn to three years) with severe airway obstruction due
to post-intubation or infectious croup were given heliox as a car-
rier for oxygen. Even though most of the children had underlying
medical problems, helium-oxygen inhalation was found to signif-
icantly reduce respiratory distress as measured by croup score and
it prevented the need for tracheal intubation. Nelson 1982 de-
scribed a further case series of 14 children (aged from three to 21
months) with viral croup who were referred for possible tracheal
intubation or tracheostomy. These children were commenced on
helium-oxygen inhalation and subsequently an improvement in
respiratory distress was observed, while none of the participants re-
quired intubation. Both case series included a heterogenous study
population and lacked a control group, which makes it very dif-
ficult to comment on the contribution of heliox mixtures to the
observed clinical outcomes. Anecdotal evidence of benefit from
heliox is further supported by Smith 1999 who reported dramatic
relief of respiratory distress in three children with croup who were
commenced on heliox therapy. A recently published retrospective
chart review by Kline-Krammes 2012 included 35 children, 17
treated with heliox and 18 controls transported by air and admit-
ted to paediatric intensive care. Those treated with heliox had a
higher baseline croup score compared to the controls. The im-
provement in croup scores in the heliox group was more rapid
and there was no difference in the number of children requiring
nebulised racaemic epinephrine during transport. The length of
stay in the paediatric intensive care unit (PICU) and hospital was
similar between the two groups.
Data from the included studies do not allow for a robust con-
clusion as to whether heliox is an effective treatment for relieving
symptoms and signs of croup in children or on rates of admission
or intubation in these children. All the studies reported changes
in croup scores while other review outcomes were not consistently
reported.We found only three trials with a total of 91 participants
that met the inclusion criteria for our review.
The first RCT to assess the effect of heliox in children with croup
was Terregino 1998. This study showed that there was no statisti-
cal significance in the mean change of croup scores pre- and post-
intervention between the control and heliox group, suggesting that
heliox was as effective but not more effective than humidified oxy-
gen in reducing croup score. A limitation, however, is the exclu-
sion of all children with severe croup who could have benefited
from the intervention and the period of gas application was short
compared to the other studies. Therefore, no conclusion can be
drawn about the benefit of heliox in children with severe croup.
None of the participants received corticosteroids or epinephrine,
contrary to current standard practice in moderate to severe croup,
making it difficult to apply the results to current clinical care.
The RCT by Weber 2001 found that overall heliox is as effective
as, but not more effective than, nebulised racaemic epinephrine
and 100% oxygen in improving croup scores. The study reported
a statistically significant improvement in the intervention group
after 90 minutes of treatment but in the absence of raw study
data this is difficult to confirm. There are a number of limitations
to this study. Participants requiring rescue nebulised epinephrine
were excluded from the analysis, as were participants who did
not tolerate the gas delivery system or had incomplete data. This
may have led to a biased estimate of the treatment effect. Another
limitation is the type of gas delivery system used to administer
helium-oxygen, as entrainment of room air would have reduced
the helium concentration of the inhaled gas mixtures and may
have diminished any beneficial effects. Tent houses, as used in
the study by Weber et al, are considered sub-optimal for heliox
delivery as helium will accumulate at the top of the tent so the
helium concentration reaching the upper airway of the patient will
be markedly reduced (Martinon-Torres 2003; Stillwell 1989).
In the RCT by Pardillo 2009, heliox was compared with no treat-
ment in childrenwith moderate croup who had been administered
corticosteroids. The study results show that treatment with heliox
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provided a greater improvement in croup scores at 60 minutes
and 120 minutes compared to baseline than no treatment. This
study also reported other outcomes that are relevant for clinical
practice. The number of participants requiring rescue adrenaline
was higher in the control group (five patients) compared to the he-
liox group (one patient), as was the number of patients who were
admitted (two in the control and one in the heliox group) but the
number of patients who re-presented for treatment at 72 hours
was similar (two patients in each group). This is the first RCT to
report these findings and it also had more participants compared
to the other two RCTs published. A limitation of the study was
that it was open-label hence the investigators knew which arms
the participants belonged to.
The duration of heliox administration varied in the three studies.
The chosen duration of 20 minutes by Terregino 1998 might have
been too short to demonstrate a significant benefit particularly
because the studies by Pardillo 2009 and Weber 2001 reported a
statistically significant difference in the improvement in the heliox
group compared to the control group after 60 and 90 minutes of
treatment respectively. Only the study by Pardillo 2009 reported
data for some other outcomes that are relevant in clinical practice
but unfortunately none of the studies fully addressed all the out-
comes of the review.
The results of the studies indicate that heliox has a positive effect
in reducing the severity of the signs and symptoms of croup as
observed from the changes in croup scores and may be beneficial
as part of initial treatment while waiting for the action of corti-
costeroids to take effect. Also there is evidence that heliox maybe
useful during transport of children with severe croup.
Quality of the evidence
The quality of the evidence from the three included trials is vari-
able. The trials by Terregino 1998 and Pardillo 2009 had a small
sample size and it is likely that these studies were underpowered
which may have resulted in a type II error and failure to find a true
effect. The study by Weber 2001 presented incomplete outcome
data which limits the quality of evidence available for interpreta-
tion. Another limitation of Pardillo 2009 was that it was an open-
label study, resulting in a high risk of performance and detection
bias.
Potential biases in the review process
Tominimise any potential bias in the review process we have used a
systematic and comprehensive search strategy. Two review authors
independently identified and reviewed records and we feel confi-
dent that reasons for exclusion were consistent and appropriate.
We have also contacted a leading medical gas supplier to enquire
about any unpublished studies to minimise the risk of publication
bias. Data analysis and extraction was carried out independently
by two review authors and interpretation of the data and outcomes
was thoroughly discussed by the whole author team. None of the
authors has any potential conflict of interest in the outcome of
this review.
Agreements and disagreements with other
studies or reviews
This review is an update of a Cochrane Review (Vorwerk 2010)
which had also been published elsewhere (Vorwerk 2008).One ad-
ditional study was identified in our updated review which slightly
changed the conclusion towards a potential benefit of heliox in
the management of croup in young children. Given the paucity
of evidence from randomised clinical trials, as more evidence be-
comes available this conclusion may be revised.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
At present there is some evidence to suggest a short-term benefit of
heliox inhalation in the treatment of moderate to severe croup in
children who have been administered oral or intramuscular dex-
amethasone. In one study, the benefit appeared to be nodifferent to
that of the combination of 100% oxygen with one to two doses of
nebulised racaemic epinephrine and in another study it appeared
slightly more beneficial than no treatment. The difference in the
croup score (Taussig score) between those administered heliox and
those without additional treatment was around one point on the
croup scale which was in the moderate range after 60 minutes.
The clinical significance of this difference is not clear. In children
with mild croup, the benefit of humidified heliox appeared to be
equivalent to that of 30% humidified oxygen, suggesting that he-
liox is not indicated in this group of patients provided that 30%
oxygen is available.
Implications for research
Adequately powered RCTs that compare heliox with standard
treatments are needed to further assess the role of heliox therapy
in the management of children with severe croup. These trials also
need to incorporate clinical outcomes with health and economic
relevance such as rate and duration of admission to paediatric in-
tensive care units, rate and duration of intubation, rate of return
to medical care for ongoing croup symptoms, rate and duration
of hospital admission, parental anxiety and side effects.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by year of study]
Terregino 1998
Methods Randomised controlled trial
Participants 15 participants (8 intervention, 7 controls) who presented to the ED with features of
croup, aged 6months to 4 years. Excluded if severe respiratory distress, oxygen saturation
< 95% on 2 L/min oxygen, or other causes of upper airway obstruction
Interventions Intervention group: humidified helium-oxygen mixture (70%/30%) for 20 minutes
Control group: humidified oxygen (30%) for 20 minutes
Outcomes Primary: change in croup score at 20 minutes
Secondary: change in heart rate, respiratory rate, oxygen saturation
Notes No information on funding source or potential conflict of interest of the authors has
been provided
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Use of sequentially, sealed envelopes available only to the
respiratory therapist
Allocation concealment (selection bias) Low risk Allocation was adequately concealed
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and outcome assessors were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No evidence of missing outcome data
Selective reporting (reporting bias) Low risk All expected study outcomes were reported
Other bias Unclear risk Convenience sample used
Weber 2001
Methods Randomised controlled trial
Participants 29 participants (14 intervention, 15 controls) who presented to the ED with features of
moderate to severe croup (corresponding to a modified Taussig croup score ≥ 5), aged 6
months to 3 years. Excluded if known congenital cardiac or tracheo-broncho-pulmonary
disease or if other causes of stridor
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Weber 2001 (Continued)
Interventions All patients received intramuscular dexamethasone 0.6 mg/kg
Intervention group: helium-oxygen inhalation (70%/30%) andup to2doses of nebulised
normal saline over 3 hours
Control group: oxygen (100%) and up to 2 doses of nebulised racaemic epinephrine
over 3 hours
Outcomes Primary: change in croup score at 30, 60, 90,120, 150, 180, 240 minutes
Secondary: change in heart rate, respiratory rate, oxygen saturation
Notes “This study was funded, in part, by theHurley Respiratory TherapyDepartment,Hurley
Medical Center.”
No information on authors’ conflict of interest provided
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Use of computer-generated randomisation scheme
Allocation concealment (selection bias) Low risk Allocation was adequately concealed
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and outcome assessors were blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Lack of ITT analysis
Selective reporting (reporting bias) High risk Lack of reporting of some of the expected outcome data
Other bias Unclear risk Given the described patient selection process there may
be a further potential risk of bias
Pardillo 2009
Methods Prospective, randomised, open clinical trial
Participants 47 participants (23 control, 24 intervention) withmoderate croup (Taussig score between
5 to 8) aged 6 to 36 months. Excluded - patients with congenital or acquired cardiac
conditions, bronchopulmonary dysplasia or stenosis or malformations of the trachea,
bronchospasm at diagnosis, intolerance of oral dexamethasone or children treated with
corticosteroids in the previous 2 weeks
Interventions All patients received oral dexamethasone 0.3 mg/kg to max of 10 mg. Rescue treatment
was nebulised epinephrine and oxygen via nasal route if saturation fell below 92%
Control group - no treatment
Intervention group - heliox 70%/30%via amask with a reservoir to prevent re-inhalation
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Pardillo 2009 (Continued)
flow rate of 10 L/min for 1 hour
Outcomes Primary outcomes: change in croup score and respiratory rate at 60 and 120 minutes
Secondary outcomes: need for nebulised rescue epinephrine, admission rate, re-consul-
tation within the following 72 hours
Notes No information on funding source or potential conflict of interest of the authors has
been provided
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Use of a computer-generated randomisa-
tion scheme
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label study; assessors knew which
arms of the study participants belonged to
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no participants lost to follow-
up
Selective reporting (reporting bias) High risk Results for the patients who required res-
cue epinephrine reported, but outcomes for
those who were admitted or who re-pre-
sented at 72 hours were not reported
Other bias Unclear risk Assessors may have influenced overall out-
comes due to the lack of blinding
ED: Emergency Department
ITT: intention-to-treat
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Beckmann 2000 Case report (2009 and 2013 searches)
Brown 2002 Review (from 2013 search)
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(Continued)
Choi 2012 Review (from 2013 search)
DiCecco 2004 Case report
Duncan 1979 Case series (2009 and 2013 searches)
Frazier 2010 Review (from 2013 search)
Gupta 2005 Review
Iglesias 2007 Cohort study
Johnson 2009 Review
Kaditis 1998 Not RCT (from 2013 search)
Kline-Krammes 2012 Review (from 2013 search)
Myers 2004 Review
Myers 2006 Review (2009 and 2013 searches)
Nelson 1982 Case series
Nicolai 2012 Review (from 2013 search)
Pitluk 2011 Not RCT (from 2013 search)
Rosekrans 1998 Not RCT (from 2013 search)
Smith 1999 Case reports
Wald 2010 Not RCT (from 2013 search)
Wright 2005 Not RCT (from 2013 search)
RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Heliox versus oxygen 30%
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean change in croup score 1 15 Mean Difference (IV, Fixed, 95% CI) 0.83 [-0.70, 2.36]
2 Westley croup score at 20 min 1 15 Mean Difference (IV, Fixed, 95% CI) -0.57 [-1.46, 0.32]
3 Heart rate at 20 min 1 15 Mean Difference (IV, Fixed, 95% CI) 14.5 [-8.49, 37.49]
4 Respiratory rate at 20 min 1 15 Mean Difference (IV, Fixed, 95% CI) 6.40 [-1.38, 14.18]
5 Oxygen saturation at 20 min 1 15 Mean Difference (IV, Fixed, 95% CI) -0.40 [-1.68, 0.88]
Comparison 2. Heliox versus placebo or no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Need for rescue adrenaline 1 47 Odds Ratio (M-H, Fixed, 95% CI) 0.16 [0.02, 1.46]
2 Taussig croup score at 60 min 1 47 Mean Difference (IV, Fixed, 95% CI) -1.12 [-2.06, -0.18]
3 Taussig croup score at 120 min 1 47 Mean Difference (IV, Fixed, 95% CI) -0.71 [-1.72, 0.30]
4 Respiratory rate at 60 min 1 47 Mean Difference (IV, Fixed, 95% CI) -4.94 [-9.66, -0.22]
5 Respiratory rate at 120 min 1 47 Mean Difference (IV, Fixed, 95% CI) -3.17 [-7.83, 1.49]
6 Number of children admitted 1 47 Odds Ratio (M-H, Fixed, 95% CI) 0.46 [0.04, 5.41]
7 Number of re-presentations to
ED
1 47 Odds Ratio (M-H, Fixed, 95% CI) 0.95 [0.12, 7.41]
Analysis 1.1. Comparison 1 Heliox versus oxygen 30%, Outcome 1 Mean change in croup score.
Review: Heliox for croup in children
Comparison: 1 Heliox versus oxygen 30%
Outcome: 1 Mean change in croup score
Study or subgroup Heliox Oxygen 30%
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Terregino 1998 8 2.25 (1.75) 7 1.42 (1.27) 100.0 % 0.83 [ -0.70, 2.36 ]
Total (95% CI) 8 7 100.0 % 0.83 [ -0.70, 2.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours heliox Favours oxygen 30%
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Analysis 1.2. Comparison 1 Heliox versus oxygen 30%, Outcome 2 Westley croup score at 20 min.
Review: Heliox for croup in children
Comparison: 1 Heliox versus oxygen 30%
Outcome: 2 Westley croup score at 20 min
Study or subgroup Heliox Oxygen 30%
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Terregino 1998 8 1 (0.76) 7 1.57 (0.97) 100.0 % -0.57 [ -1.46, 0.32 ]
Total (95% CI) 8 7 100.0 % -0.57 [ -1.46, 0.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.25 (P = 0.21)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours heliox Favours oxygen 30%
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Analysis 1.3. Comparison 1 Heliox versus oxygen 30%, Outcome 3 Heart rate at 20 min.
Review: Heliox for croup in children
Comparison: 1 Heliox versus oxygen 30%
Outcome: 3 Heart rate at 20 min
Study or subgroup Heliox Oxygen 30%
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Terregino 1998 8 152.4 (30.5) 7 137.9 (12.2) 100.0 % 14.50 [ -8.49, 37.49 ]
Total (95% CI) 8 7 100.0 % 14.50 [ -8.49, 37.49 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.24 (P = 0.22)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours heliox Favours oxygen 30%
Analysis 1.4. Comparison 1 Heliox versus oxygen 30%, Outcome 4 Respiratory rate at 20 min.
Review: Heliox for croup in children
Comparison: 1 Heliox versus oxygen 30%
Outcome: 4 Respiratory rate at 20 min
Study or subgroup Heliox Oxygen 30%
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Terregino 1998 8 33.8 (9.5) 7 27.4 (5.6) 100.0 % 6.40 [ -1.38, 14.18 ]
Total (95% CI) 8 7 100.0 % 6.40 [ -1.38, 14.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.61 (P = 0.11)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours heliox Favours oxygen 30%
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Analysis 1.5. Comparison 1 Heliox versus oxygen 30%, Outcome 5 Oxygen saturation at 20 min.
Review: Heliox for croup in children
Comparison: 1 Heliox versus oxygen 30%
Outcome: 5 Oxygen saturation at 20 min
Study or subgroup Heliox Oxygen 30%
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Terregino 1998 8 99 (1.5) 7 99.4 (1) 100.0 % -0.40 [ -1.68, 0.88 ]
Total (95% CI) 8 7 100.0 % -0.40 [ -1.68, 0.88 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours heliox Favours oxygen 30%
Analysis 2.1. Comparison 2 Heliox versus placebo or no treatment, Outcome 1 Need for rescue adrenaline.
Review: Heliox for croup in children
Comparison: 2 Heliox versus placebo or no treatment
Outcome: 1 Need for rescue adrenaline
Study or subgroup Heliox Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Pardillo 2009 1/24 5/23 100.0 % 0.16 [ 0.02, 1.46 ]
Total (95% CI) 24 23 100.0 % 0.16 [ 0.02, 1.46 ]
Total events: 1 (Heliox), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.63 (P = 0.10)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours heliox Favours control
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Analysis 2.2. Comparison 2 Heliox versus placebo or no treatment, Outcome 2 Taussig croup score at 60
min.
Review: Heliox for croup in children
Comparison: 2 Heliox versus placebo or no treatment
Outcome: 2 Taussig croup score at 60 min
Study or subgroup Heliox Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Pardillo 2009 24 2.62 (1.69) 23 3.74 (1.6) 100.0 % -1.12 [ -2.06, -0.18 ]
Total (95% CI) 24 23 100.0 % -1.12 [ -2.06, -0.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.33 (P = 0.020)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours heliox Favours control
Analysis 2.3. Comparison 2 Heliox versus placebo or no treatment, Outcome 3 Taussig croup score at 120
min.
Review: Heliox for croup in children
Comparison: 2 Heliox versus placebo or no treatment
Outcome: 3 Taussig croup score at 120 min
Study or subgroup Heliox Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Pardillo 2009 24 1.46 (1.25) 23 2.17 (2.16) 100.0 % -0.71 [ -1.72, 0.30 ]
Total (95% CI) 24 23 100.0 % -0.71 [ -1.72, 0.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours heliox Favours control
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Analysis 2.4. Comparison 2 Heliox versus placebo or no treatment, Outcome 4 Respiratory rate at 60 min.
Review: Heliox for croup in children
Comparison: 2 Heliox versus placebo or no treatment
Outcome: 4 Respiratory rate at 60 min
Study or subgroup Heliox Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Pardillo 2009 24 30.67 (7.2) 23 35.61 (9.15) 100.0 % -4.94 [ -9.66, -0.22 ]
Total (95% CI) 24 23 100.0 % -4.94 [ -9.66, -0.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.05 (P = 0.040)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours heliox Favours control
Analysis 2.5. Comparison 2 Heliox versus placebo or no treatment, Outcome 5 Respiratory rate at 120 min.
Review: Heliox for croup in children
Comparison: 2 Heliox versus placebo or no treatment
Outcome: 5 Respiratory rate at 120 min
Study or subgroup Heliox Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Pardillo 2009 24 29 (7.82) 23 32.17 (8.44) 100.0 % -3.17 [ -7.83, 1.49 ]
Total (95% CI) 24 23 100.0 % -3.17 [ -7.83, 1.49 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.33 (P = 0.18)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours heliox Favours control
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Analysis 2.6. Comparison 2 Heliox versus placebo or no treatment, Outcome 6 Number of children
admitted.
Review: Heliox for croup in children
Comparison: 2 Heliox versus placebo or no treatment
Outcome: 6 Number of children admitted
Study or subgroup Heliox Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Pardillo 2009 1/24 2/23 100.0 % 0.46 [ 0.04, 5.41 ]
Total (95% CI) 24 23 100.0 % 0.46 [ 0.04, 5.41 ]
Total events: 1 (Heliox), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.53)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours heliox Favours control
Analysis 2.7. Comparison 2 Heliox versus placebo or no treatment, Outcome 7 Number of re-presentations
to ED.
Review: Heliox for croup in children
Comparison: 2 Heliox versus placebo or no treatment
Outcome: 7 Number of re-presentations to ED
Study or subgroup Heliox Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Pardillo 2009 2/24 2/23 100.0 % 0.95 [ 0.12, 7.41 ]
Total (95% CI) 24 23 100.0 % 0.95 [ 0.12, 7.41 ]
Total events: 2 (Heliox), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.96)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours heliox Favours control
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A D D I T I O N A L T A B L E S
Table 1. Summary of studies table
Authors Number of par-
ticipants
Croup severity Pre-randomisa-
tion treatment
Intervention
and duration of
administration
Comparison
and duration of
administration
Outcome time
points
Terregino 1998 15 Mild None Hu-
midified helium-
oxygen mixture
70%/30% over
20 minutes
Humidified oxy-
gen 30% over 20
minutes
Immediate -
20 minutes post-
treatment
Weber 2001 29 Moderate to se-
vere
Intramus-
cular dexametha-
sone 0.6 mg/kg
He-
lium-oxygen in-
halation (70%/
30%) and up to
2 normal saline
nebulisers over 3
hours
Oxygen (100%)
and up to 2 doses
of neb-
ulised racaemic
epinephrine over
3 hours
Imme-
diate - 30 min-
utes, medium -
60 and 90 min-
utes, long-term
120, 180 and
240 minutes
Pardillo 2009 47 Moderate Oral dexametha-
sone 0.3 mg/kg
Helium-oxygen
70%/30% over 1
hour
No treatment Immedi-
ate - no, medium
- 60 minutes,
long-term - 120
minutes
A P P E N D I C E S
Appendix 1. Details of previous search
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2009, Issue 2) which contains the
Cochrane Acute Respiratory Infections (ARI) Group’s Specialised Register; MEDLINE (1950 to June week 3 2009); EMBASE (1974
to 2009 week 25) and CINAHL (1982 to June 2009).
MEDLINE and CENTRAL were searched using the following terms. The search terms were adapted for EMBASE and CINAHL.
MEDLINE (Ovid)
1 exp Croup/
2 laryngotracheit*.mp.
3 laryngotracheo*.mp.
4 “laryngo tracheo bronchit*”.mp.
5 croup.mp.
6 helium.mp.
7 heliox.mp.
8 “he-O2”.mp.
9 heO2.mp.
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10 “he O2”.mp.
11 exp Helium/
12 “young adult*”.mp.
13 (infant* or baby or babies or newborn* or paediatric* or pediatric* or child* or teen* or neonat* or adolescen*).mp.
14 1 or 2 or 3 or 4 or 5
15 6 or 7 or 8 or 9 or 10 or 11
16 12 or 13
17 14 and 15 and 16
EMBASE (Ovid) 1980 to Week 25 2009
1 exp Croup/
2 croup.mp.
3 laryngotracheit*.mp.
4 “laryngo tracheo bronchit*”.mp.
5 laryngotracheo*.mp.
6 exp Helium/
7 exp Heliox/
8 helium.mp.
9 heliox.mpl
10 “He-O2”.mp.
11 HeO2.mp.
12 “young adult*”.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug
manufacturer name] (31526)
13 (infant* or baby or babies or newborn* or paediatric* or pediatric* or child* or teen* or neonat* or adolescen*).mp. [mp=title,
abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name] (1308855)
14 1 or 2 or 3 or 4 or 5
15 6 or 7 or 8 or 9 or 10 or 11
16 12 or 13
17 14 and 15 and 16
CINAHL (NHS Healthcare Databases Advanced Search) 1981 to 26 June 2009
1. CROUP/
2. laryngotracheo*.af.
3. croup.af.
4. laryngotracheit*.af.
5. “laryngo trachea bronchit*”.af.
6. HELIUM/
7. helium.af.
8. heliox.af.
9. “he-O2”.af.
10. “he O2”.af.
11. heO2.af.
12. (infant* OR baby OR babies OR newborn* OR pediatric* OR paediatric* OR child* OR teen* OR neonat* OR adolescen*).af.
13. “young adult*”.af.
14. 1 OR 2 OR 3 OR 4 OR 5
15. 6 OR 7 OR 8 OR 9 OR 10 OR 11
16. 12 OR 13
17. 14 AND 15 AND 16
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Appendix 2. EMBASE (Elsevier) search strategy
#13 #7 AND #12
#12 #8 OR #9 OR #10 OR #11
#11 heo2:ab,ti OR ’he-o2’:ab,ti OR ’he o2’:ab,ti
#10 helium*:ab,ti OR heliox:ab,ti
#9 ’heliox’/de
#8 ’helium’/de
#7 #1 OR #2 OR #3 OR #4 OR #5 OR #6
#6 parainfluenza*:ab,ti
#5 ’parainfluenza virus 1’/de OR ’parainfluenza virus 2’/de OR ’parainfluenza virus’/de
#4 laryngotracheo*:ab,ti OR laryngotracheit*:ab,ti OR ’laryngo tracheo bronchitis’:ab,ti OR ’laryngo-tracheo-bronchitis’:ab,ti
#3 ’laryngotracheobronchitis’/de
#2 croup:ab,ti
#1 ’croup’/de
Appendix 3. CINAHL search strategy
S11 S4 and S10 S
S10 S5 or S6 or S7 or S8 or S9
S9 TI helium N1 oxygen OR AB helium N1 oxygen
S8 TI ( heo2 or “he o2” or “he-o2” ) OR AB ( heo2 or “he o2” or “he-o2” )
S7 TI heliox OR AB heliox
S6 TI helium* OR AB helium*
S5 (MH “Helium”) S
S4 S1 or S2 or S3
S3 TI (laryngotracheit* or laryngotracheo* or “laryngo tracheo bronchitis” or “laryngo-tracheo-bronchitis”) OR AB (laryngotracheit*
or laryngotracheo* or “laryngo tracheo bronchitis” or “laryngo-tracheo-bronchitis”)
S2 TI croup OR AB croup OR TI parainfluenza* OR AB parainfluenza*
S1 (MH “Croup”)
Appendix 4. Web of Science (Thomson Reuters) search strategy
Topic=(croup or laryngotracheit* or laryngotracheo* or laryngotracheobronchit* or laryngo-tracheo-bronchit* or parainfluenza*) AND
Topic=(helium* or heliox or heo2 or he-o2 or “he o2”)
Time span = All Years. Databases = SCI-EXPANDED, CPCI-S.
Appendix 5. LILACS (BIREME) search strategy
(mh:croup OR croup OR crup OR crupe OR mh:“Parainfluenza Virus 1, Human” OR mh:“Parainfluenza Virus 2, Human” OR
mh:“Parainfluenza Virus 3, Human” OR parainfluenza* OR laryngotracheobronchit* OR laryngotracheit* OR “laryngo tracheo
bronchitis” OR “laryngo-tracheo-bronchitis” OR “Virus de la Laringotraqueobronquitis Aguda”OR “Virus Crup-Asociado” OR “Vírus
da Laringotraqueobronquite Aguda” OR “Vírus Associado a Crupe”) AND (mh:helium OR helium* OR helio OR hélio OR heliox
OR heo2 OR “he o2” OR “he-o2”) AND db:(“LILACS”)
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WH A T ’ S N E W
Last assessed as up-to-date: 12 November 2013.
Date Event Description
12 November 2013 New citation required and conclusions have changed One new included trial added to the evidence in favour
of using heliox in children with moderate to severe
croup
12 November 2013 New search has been performed Searches updated.We identified one new included trial
(Pardillo 2009) and excluded 10 new trials (Brown
2002; Choi 2012; Frazier 2010; Kaditis 1998; Kline-
Krammes 2012; Nicolai 2012; Pitluk 2011; Rosekrans
1998; Wald 2010; Wright 2005).
H I S T O R Y
Protocol first published: Issue 4, 2007
Review first published: Issue 2, 2010
Date Event Description
7 September 2012 Amended Withdrawn.
8 July 2008 Amended Converted to new review format.
C O N T R I B U T I O N S O F A U T H O R S
This review is based on the withdrawn review by C Vorwerk and TJ Coats. The current author team updated the searches, added one
new study and made considerable changes to the text.
IM led the review team and IM and NS drafted the review. MLVD provided methodological support and TM provided content
expertise. All authors contributed to the draft and interpretation of the findings and approved the final version of the review.
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D E C L A R A T I O N S O F I N T E R E S T
None.
S O U R C E S O F S U P P O R T
Internal sources
• Funding, Not specified.
None
External sources
• Funding, Not specified.
None
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
No changes were made to the methodology applied in the withdrawn review.
N O T E S
The secondary outcomes in this 2013 updated review have been expanded to be consistent with other Cochrane Reviews of interventions
for croup.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Adrenal Cortex Hormones [therapeutic use]; Airway Obstruction [etiology; ∗therapy]; Airway Resistance [drug effects]; Bronchodila-
tor Agents [therapeutic use]; Croup [∗complications]; Dexamethasone [therapeutic use]; Epinephrine [therapeutic use]; Helium
[∗administration & dosage]; Oxygen [∗administration & dosage]; Oxygen Inhalation Therapy [methods]; Randomized Controlled
Trials as Topic
MeSH check words
Child, Preschool; Humans; Infant
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